- Global network
- About us
-
Knowledge hub
Clinical Trial Supply & Logistics
- Clinical Trial Logistics
- Clinical Trial Supply
- Courier Services & Preconditioned Temperature Controlled Packaging
- GxP-Compliant Cold Chain Transport & Storage
- Decentralised Clinical Trials & Direct-to-Patient Logistics
- Labelling of Medicinal Products
- Laboratory Kits Preparation
- Protocol Review & Project Management
Medicines Access & Patient-Oriented Services
Regulatory & Importation Services
25.05.2026
Cold Chain, Hot Problems: The True Cost of Temperature Excursions
Let’s imagine a scenario.
A shipment leaves Europe under controlled conditions – validated route, qualified cold chain packaging, and stable temperatures throughout transit. Everything is aligned with pharma cold chain requirements. It arrives in Central Asia. The external temperature is 35°C higher than at origin. Mid-transit, the data logger battery fails.
No alerts.
No real-time monitoring.
No cold chain visibility.
From a documentation standpoint, everything still appears compliant. But there is no continuous temperature record. Now the question isn’t operational – it’s critical:
Can the product still be used or has a temperature excursion in pharma already occurred without being detected?
Real-world cases illustrate how these risks materialize in practice.
In one reported case, shipments of the AstraZeneca COVID-19 vaccine arrived with indicators suggesting exposure to out-of-range conditions during transit. However, uncertainty around how to interpret this data led to delays in decision-making at the clinical site.
The scale of the challenge is growing rapidly. The global cold chain market was valued at approximately USD 371.08 billion in 2025 and is expected to grow significantly faster than the broader logistics sector, driven by increasing demand for biologics, vaccines, and other temperature-sensitive therapies.
As pharmaceutical supply chain management becomes more complex and biologics temperature sensitivity increases, the consequences of cold chain failure extend far beyond product loss. Understanding the cost of temperature excursion means looking beyond the immediate shipment – it includes patient dropout, recruitment delays, and cascading trial impacts.
A single undetected deviation can mean a patient misses a dosing window. In clinical trials, it can lead to patient dropout, requiring costly and time-consuming replacement. Recruitment, screening, and onboarding of a new patient can take weeks or even months, significantly impacting study timelines. A systematic review analyzing 80 peer-reviewed studies published between 2007 and 2024 found that delays in pharmaceutical cold chain logistics are not limited to last-mile delivery challenges. They occur throughout the supply chain, particularly in upstream stages such as production and international logistics. These delays can trigger cascading effects, ultimately impacting product quality at the point of use. Importantly, inefficiencies in the cold chain are estimated to result in the loss of up to 35% of pharmaceutical products, highlighting the scale of both visible and hidden wastage. This reinforces the idea that cold chain failures are not isolated events, but the result of interconnected risks across the system.
What appears as a cold chain failure at the logistics level quickly becomes a clinical and financial risk – affecting patients, trial integrity, and overall development timelines.
If temperature excursions are inevitable, the question becomes:
How do you reduce their likelihood and their impact?
This has become increasingly important as regulatory expectations continue to evolve. The pharmaceutical cold chain is governed by stringent standards such as European Medicines Agency Good Distribution Practice guidelines, which aim to ensure the quality and integrity of temperature-sensitive products throughout transportation and storage. More broadly, regulators worldwide are moving toward greater standardization of cold chain requirements placing increased emphasis on monitoring, traceability, and end-to-end control across healthcare supply chains.
In the pharma cold chain, prevention is not about a single solution. It’s about closing the gaps where failures occur.
1. Design for Real Conditions, Not Ideal Scenarios
Geopolitical instability adds another layer of complexity. Disruptions in key transit corridors, including regions around the Persian Gulf, can lead to sudden rerouting, extended transit times, and unexpected exposure to uncontrolled conditions. As a result, assumptions made during validation often no longer hold in real operations.
2. Match Transport and Packaging to Product Risk
Not all products require the same level of control; however, underestimating risk remains one of the most common failure points in the pharma cold chain.
For high-value or biologics with extreme temperature sensitivity, understanding pharmaceutical cold chain risk is critical:
In practice, effective temperature-controlled transportation depends on aligning three elements: product sensitivity, route risk, and handling requirements.
This is where specialized partners such as COREX play a critical role ensuring that packaging, routing, and handling strategies are tailored to the actual risk profile of each shipment, rather than applied as a one-size-fits-all solution. Learn more about our GxP-compliant cold chain transport and storage solutions.
3. Maintain End-to-End Cold Chain Custody
Maintaining cold chain integrity requires continuous control – from pharmaceutical cold storage at the depot through packaging, transit, and final delivery. This makes route analysis critical in cold chain logistics.
This makes route analysis critical in cold chain logistics. Transit delays, climate conditions, customs handling, and multiple handoffs can all increase the risk of temperature excursions during the journey. COREX's clinical trial logistics services are designed to maintain full custody and visibility across these complex routes.
Without full visibility across the shipment route, even validated transportation strategies may fail under real-world conditions.
4. Eliminate Blind Spots in Monitoring
Having cold chain monitoring is not the same as having control. Key risks include:
Closing these gaps requires more than technology it requires integration. Effective solutions combine real-time monitoring with clear response procedures, so that temperature deviations are not only detected, but also quickly addressed.
5. Address the Human Factor
Even the most advanced systems fail when people do not interact with them correctly. Common issues include:
Reducing failures requires:
Effective cold chain management depends on processes designed not just for compliance, but for real-world usability.
6. Plan for Failure, Not Just Prevention
Not every temperature excursion can be avoided. What matters is how quickly and effectively the response is managed. This includes:
An estimated 70% of biopharmaceutical products require temperature-controlled handling highlighting how critical cold chain integrity is across the industry. Temperature deviations remain a critical risk in cold chain logistics. However, an equally important challenge lies in the false sense of control when systems appear compliant, but gaps in monitoring or response still exist.
Mark Woolf concludes: "Cold chain failure prevention isn't about eliminating every risk – that's impossible. It's about building systems where failures are detected immediately, where pharmaceutical cold chain risk is continuously assessed, and where everyone from the warehouse to the clinical site knows exactly what to do when something goes wrong. That's the difference between a temperature excursion becoming a data point or becoming a patient safety issue."
A shipment leaves Europe under controlled conditions – validated route, qualified cold chain packaging, and stable temperatures throughout transit. Everything is aligned with pharma cold chain requirements. It arrives in Central Asia. The external temperature is 35°C higher than at origin. Mid-transit, the data logger battery fails.
No alerts.
No real-time monitoring.
No cold chain visibility.
From a documentation standpoint, everything still appears compliant. But there is no continuous temperature record. Now the question isn’t operational – it’s critical:
Can the product still be used or has a temperature excursion in pharma already occurred without being detected?
Real-world cases illustrate how these risks materialize in practice.
In one reported case, shipments of the AstraZeneca COVID-19 vaccine arrived with indicators suggesting exposure to out-of-range conditions during transit. However, uncertainty around how to interpret this data led to delays in decision-making at the clinical site.
The scale of the challenge is growing rapidly. The global cold chain market was valued at approximately USD 371.08 billion in 2025 and is expected to grow significantly faster than the broader logistics sector, driven by increasing demand for biologics, vaccines, and other temperature-sensitive therapies.
As pharmaceutical supply chain management becomes more complex and biologics temperature sensitivity increases, the consequences of cold chain failure extend far beyond product loss. Understanding the cost of temperature excursion means looking beyond the immediate shipment – it includes patient dropout, recruitment delays, and cascading trial impacts.
A single undetected deviation can mean a patient misses a dosing window. In clinical trials, it can lead to patient dropout, requiring costly and time-consuming replacement. Recruitment, screening, and onboarding of a new patient can take weeks or even months, significantly impacting study timelines. A systematic review analyzing 80 peer-reviewed studies published between 2007 and 2024 found that delays in pharmaceutical cold chain logistics are not limited to last-mile delivery challenges. They occur throughout the supply chain, particularly in upstream stages such as production and international logistics. These delays can trigger cascading effects, ultimately impacting product quality at the point of use. Importantly, inefficiencies in the cold chain are estimated to result in the loss of up to 35% of pharmaceutical products, highlighting the scale of both visible and hidden wastage. This reinforces the idea that cold chain failures are not isolated events, but the result of interconnected risks across the system.
What appears as a cold chain failure at the logistics level quickly becomes a clinical and financial risk – affecting patients, trial integrity, and overall development timelines.
If temperature excursions are inevitable, the question becomes:
How do you reduce their likelihood and their impact?
This has become increasingly important as regulatory expectations continue to evolve. The pharmaceutical cold chain is governed by stringent standards such as European Medicines Agency Good Distribution Practice guidelines, which aim to ensure the quality and integrity of temperature-sensitive products throughout transportation and storage. More broadly, regulators worldwide are moving toward greater standardization of cold chain requirements placing increased emphasis on monitoring, traceability, and end-to-end control across healthcare supply chains.
In the pharma cold chain, prevention is not about a single solution. It’s about closing the gaps where failures occur.
1. Design for Real Conditions, Not Ideal Scenarios
Geopolitical instability adds another layer of complexity. Disruptions in key transit corridors, including regions around the Persian Gulf, can lead to sudden rerouting, extended transit times, and unexpected exposure to uncontrolled conditions. As a result, assumptions made during validation often no longer hold in real operations.
2. Match Transport and Packaging to Product Risk
Not all products require the same level of control; however, underestimating risk remains one of the most common failure points in the pharma cold chain.
For high-value or biologics with extreme temperature sensitivity, understanding pharmaceutical cold chain risk is critical:
- Standard courier services may not provide sufficient control
- White glove temperature-controlled shipping, where shipments are handled by trained specialists with minimal handoffs, significantly reduces handling-related risks
- Advanced cold chain packaging must be selected based on transit duration, route complexity, and external environmental conditions – particularly for ultra-cold and cryogenic transport requirements
In practice, effective temperature-controlled transportation depends on aligning three elements: product sensitivity, route risk, and handling requirements.
This is where specialized partners such as COREX play a critical role ensuring that packaging, routing, and handling strategies are tailored to the actual risk profile of each shipment, rather than applied as a one-size-fits-all solution. Learn more about our GxP-compliant cold chain transport and storage solutions.
3. Maintain End-to-End Cold Chain Custody
Maintaining cold chain integrity requires continuous control – from pharmaceutical cold storage at the depot through packaging, transit, and final delivery. This makes route analysis critical in cold chain logistics.
This makes route analysis critical in cold chain logistics. Transit delays, climate conditions, customs handling, and multiple handoffs can all increase the risk of temperature excursions during the journey. COREX's clinical trial logistics services are designed to maintain full custody and visibility across these complex routes.
Without full visibility across the shipment route, even validated transportation strategies may fail under real-world conditions.
4. Eliminate Blind Spots in Monitoring
Having cold chain monitoring is not the same as having control. Key risks include:
- battery failure in data loggers
- lack of real-time alerts
- gaps in visibility during handoffs
Closing these gaps requires more than technology it requires integration. Effective solutions combine real-time monitoring with clear response procedures, so that temperature deviations are not only detected, but also quickly addressed.
5. Address the Human Factor
Even the most advanced systems fail when people do not interact with them correctly. Common issues include:
- devices not being activated
- incorrect placement of sensors
- delayed response to alerts
Reducing failures requires:
- targeted training at transit points and clinical sites
- simplified standard operating procedures (SOPs)
- clear ownership of decision-making
Effective cold chain management depends on processes designed not just for compliance, but for real-world usability.
6. Plan for Failure, Not Just Prevention
Not every temperature excursion can be avoided. What matters is how quickly and effectively the response is managed. This includes:
- predefined decision trees for excursions
- clear criteria for product usability
- rapid communication between stakeholders
An estimated 70% of biopharmaceutical products require temperature-controlled handling highlighting how critical cold chain integrity is across the industry. Temperature deviations remain a critical risk in cold chain logistics. However, an equally important challenge lies in the false sense of control when systems appear compliant, but gaps in monitoring or response still exist.
Mark Woolf concludes: "Cold chain failure prevention isn't about eliminating every risk – that's impossible. It's about building systems where failures are detected immediately, where pharmaceutical cold chain risk is continuously assessed, and where everyone from the warehouse to the clinical site knows exactly what to do when something goes wrong. That's the difference between a temperature excursion becoming a data point or becoming a patient safety issue."
